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Acute Coronary Syndromes
Higher Clopidogrel Loading Doses
Achieve Faster, Stronger Platelet Inhibition
There is some discrepancy in the literature about the optimal loading dose ofclopidogrel. Montalescot and colleagues randomized 100 patients with acute
coronary syndromes to either 300, 600, or 900mg of clopidogrel. Blood samples were
then collected for the next 24 h to determine the optimal regimen for rapid and reliable
inhibition of adenosine diphosphate-induced platelet aggregation. Both 600- and
900-mg doses resulted in platelet inhibition that was faster and more robust than
300-mg doses; there was a trend suggesting that 900 mg was more effective than
600mg.No adverse events were apparent with the higher loading doses. Larger studies
will be needed to know if this faster platelet inhibition leads to improved clinical
outcomes, but this study suggests that 300 mg may not be enough to quickly inhibit
platelet aggregation. See page 931. See figure.
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Coronary Artery Disease
Physician Preference Leads to Superior Outcomes for CABG Versus PCI
There is still no consensus on the best treatment for patients with stablemultivesselcoronary artery disease and preserved left ventricular function. The MASS II
(Medicine, Angioplasty, or Surgery Study II) randomized patients deemed eligible for
each to 1 of the 3 treatments strategies. Prior to randomization, 2 physicianswere asked
their personal recommendation for the subjects based on their clinical situation. For
this current study, subjects were stratified according to whether or not they were
randomized to the clinician-preferred strategy. Subjects for whom the clinician prefer-
ence and the randomizationwere concordantwere found to have superior outcomes to
those where there was discordance. Further probing of the data revealed that the
difference was mostly due to patients with complex anatomy being referred for
percutaneous coronary intervention and then having to undergo subsequent revascu-
larizations. This study suggests that clinical judgment is an important criterion when
choosing between revascularization options. See page 948. See figure.
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Coronary Artery Disease
Preoperative Stress Testing May Not be Necessary
Current American College of Cardiology/American Heart Association guidelinesrecommend preoperative evaluations for ischemia in high- and intermediate-risk
patients scheduled for moderate or high-risk surgeries, but the benefit of preoperative
revascularization has been questioned. Delaying surgery until stress testing and/or
revascularization can occur may put patients at unneeded risk from their underlying
condition. The DECREASE-II study sought to evaluate the benefit of preoperative
stress testing in patients assigned to a fairly aggressive regimen of beta blockade. There
were 2major findings in this study. First, there was no benefit in reduction of non-fatal
myocardial infarctions at 30 days for preoperative stress testing and second, the risk of
this end point directly correlated with the heart rate at the time of surgery. This study
suggests that not all intermediate-risk patients referred for surgery benefit from preop-
erative stress testing and that perioperative beta blockade should be titrated to a target
heart rate 65 beats/min. See page 964. See figure.
(continued) A-40Heart Rhythm Disorders
No Benefit to Early Cardioversion for Atrial Fibrillation
Atrial electrical remodeling is known to occur quickly with atrial fibrillation (AF)andhas led to thebelief that the longer apatient is inAFprior to cardioversion, the
less likely they are to be successfully cardioverted. TheVERDICT trial was designed to
test the hypothesis that early cardioversion will reduce AF recurrences and be more
successful for long-term maintenance of sinus rhythm. A second aim of the study was
to test whether verapamil was superior to digoxin for preventing AF by reducing atrial
calcium overload. Patients were randomized in a 2 2 factorial design to either acute
cardioversion within 24 h for each episode of AF or regularly scheduled cardioversion,
and then randomized to either verapamil or digoxin for rate control. Neither strategy
was superior to the other, although digoxin without beta blockade appeared to be
inferior to verapamil. This study challenges the notions that elective AF cardioversions
should be scheduled as quickly as possible, and that calcium-channel blockers are the
preferred agent for reducing the likelihood of AF reversion. See page 1001.
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Cardiac Imaging
Strong Correlation Between Coronary Artery
Calcification and Reduced Myocardial Perfusion
Coronary artery calcification (CAC) detected by computed tomography has beencorrelated with perfusion defects and increased cardiovascular risk. Investigators
from the MESA trial compared CAC with MRI-measured myocardial perfusion at
baseline and during hyperemia. In this asymptomatic cohort, there was a strong and
inverse association between CAC and myocardial perfusion, suggesting that CAC is
not only a marker of a greater likelihood of hemodynamically significant stenoses, but
may also correlate with endothelial dysfunction. This study provides evidence that
CAC, thought to be an indicator of structural stenoses, is closely linked with and
complementary to physiologic measures of myocardial perfusion. See page 1018.
See figure.
